Terns Pharmaceuticals (NASDAQ:TERN) is down ~14% in after-hours trading Tuesday after saying it would abandon its oral GLP-1 receptor agonist for weight loss, TERN-601, due to disappointing phase 2 results.
Topline 12-week data found a maximum placebo-adjusted weight loss of
